Children with constitutional trisomy 21 or Down's syndrome (DS) are predisposed to develop myeloid leukemia (ML) at a young age. DS-ML is frequently preceded by transient leukemia (TL), a spontaneously resolving accumulation of blasts during the newborn period. Somatic mutations of GATA1 in the blasts of TL and DS-ML likely function as an initiating event. We hypothesized that the phenotypic difference between TL and DS-ML is due to a divergent functional repertoire of the leukemia-initiating cells. Using an NOD/SCID model, we found that cells initiating DS-ML engrafted, disseminated to distant bone marrow sites, and propagated the leukemic clone in secondary recipients. In contrast, TL cells lacked the ability to expand and to migrate, but were able to persist in the recipient bone marrow. We found some evidence of genomic progression with 1 of 9 DS-ML samples and none of 11 TL samples harboring a mutation of N-RAS. The findings of this pilot study provide evidence for the functional impact of second events underlying the transformation of TL into DS-ML and a needed experimental tool for the functional testing of these promoting events.
Introduction
Myeloid leukemia (ML) in children with constitutional trisomy 21 or Down's syndrome (DS; OMIM 190685) provides unique insight into the incremental process that underlies leukemic transformation. ML in DS is 150-fold more frequent than in the general population and develops early, during the first 4 years of life.
1,2 Transient leukemia (TL), a spontaneously reversible accumulation of megakaryocytic blasts in the blood of 10% of newborns with DS, [3] [4] [5] represents a putative precursor of leukemia in this group. Somatic mutations of GATA1, present in both TL and DS-ML blasts, [6] [7] [8] [9] [10] likely function as the initiating 'first event.' 11, 12 After the identification of initiating cells in numerous human leukemias, 13 differences during disease evolution are beginning to emerge. In acute lymphoblastic leukemia, for example, pre-leukemic cells are related to, but functionally less potent than leukemia-initiating cells. 14 We hypothesized that the progression from TL to DS-ML, as the result of yet unknown 'second events,' is reflected in a functional difference between TL and DS-ML-initiating cells that this difference is detectable using state of the art in vivo repopulation assays and thus provide a powerful tool to establish the functional relevance of presumed second events. We provide a first reliable in vivo model of DS leukemia and use it to characterize the functional properties of cells initiating DS-AML and their difference to TL.
Materials and methods

Cells and transplantation method
We established experimental models of DS-ML and TL by transplanting cryopreserved mononuclear primary human cells into NOD/SCID mice. Blood or bone marrow cells of patients were used according to a research protocol approved by the institutional Research Ethics Board. DS, DS-ML, and TL were diagnosed by standard karyotyping, cytology, and immunophenotyping methods, respectively.
Transplantation assay
Eight-week-old NOD/SCID mice (bred at the University Health Network, Toronto) were irradiated (3.25 Gy), treated with anti-CD122 antibody 15 to suppress NK cell function, and injected into their right femur with primary human cells as described earlier. 16 Human hematopoietic growth factors (SCF 10 mg, IL-3 0.6 mg, and thrombopoietin 1.2 mg) were administered intraperitoneally (2-3 times per week) to recipients during the first 2 weeks after transplantation. The same method was used in secondary transplant and limiting dilution experiments.
Phenotypic analysis
Approximately 8 weeks after transplantation, recipients' injected (right femur), non-injected bone marrow sites, spleen, and liver were analyzed using standard cytological, histological, and flow-cytometric methods.
Flow cytometry
For analytical reactions, approximately 5 Â 10 5 cells were labeled with the following murine anti-human monoclonal antibodies: anti-CD45-PC5 (Beckman Coulter, Fullerton, CA, USA), anti-CD61-FITC, anti-CD34-PE, anti-RAC1-FITC, anti-CD44-PE, anti-CD184-PC5, anti-CD117-PE (BD Bioscience, San Jose, CA, USA) or their respective isotype controls, and analyzed on an FACSCalibur flowcytometer (Becton Dickinson, San Jose, CA, USA). For cell sorting experiments, cells were labeled with anti-CD45-FITC (BD), anti-CD34-PC5 (BD), and anti-CD38-PE (BD) or anti-CD45-PC5 (Beckman Coulter), anti-CD61-FITC (BD), anti-CD34-PC5 (BD), and sorted on an FACSAria (BD) cell sorter. Fractions with a viability and purity of at least 95% were used in subsequent experiments.
DNA isolation and mutational analysis
Genomic DNA of primary and engrafted human samples was analyzed as described earlier. 6 Genomic DNA corresponding to exon 2 of GATA1 (accession no. NW_927703, cDNA accession no. NM_002049) was amplified by PCR (AmpliTaq Gold DNA Polymerase, Applied Biosystems, Foster City, CA, USA) using flanking oligonucleotide primers specific for human GATA1 (forward primer, 5 0 -GGGAAGGAGAGGGGAGACTA-3 0 ; reverse primer 5 0 -GGGCAACCACCACATACTTC-3 0 ) after a standard protocol (95 1C for 8 min followed by 35 cycles of 15 s at 95 1C, 30 s at 60 1C, and 60 s at 72 1C, and a final incubation at 72 1C for 10 min). Somatic mutations within and adjacent to exon 2 of GATA1 were detected by sequencing of the amplification products both directly and after subcloning (QIAGEN PCR Cloning kit, Mississauga, Canada). Long-range PCR (LA PCR kit, Shiga, Japan) was used to detect large deletions encompassing the annealing sites of the primers described above (forward primers within exon 1 (5 0 -AGGACACCCCCTGGGATC-3 0 ); reverse primer within exon 3 (5 0 -CTCCATACAGTTGAGCAATGGG -3 0 )). 8 Reaction conditions included an incubation at 94 1C for 1 min followed by 30 cycles of 20 s at 94 1C, 40 s at 62 1C, and 6 min at 68 1C followed by a final 10 min incubation at 68 1C. PCR products were purified from a 1% agarose gel (QIAEX II Gel Extraction kit, Mississauga, Canada) and directly sequenced to confirm the break point of large GATA1 deletions. Primer sequences for the analysis of mutations in the genes encoding N-RAS, K-RAS, c-KIT, and FLT3 are found in Supplementary  Table 1 . Sequence comparisons were performed using programs available from the National Centre for Biotechnology Information (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Fluorescence in situ hybridization
Bone marrow cells were added to pre-warmed hypotonic solution (0.075 M KCl) and incubated for 15 min at 37 1C. After addition of pre-fixative at room temperature (3:1, v/v; methanol: glacial acetic acid), cells underwent three rounds of fixation (centrifugation, addition of cold 3:1, v/v; methanol: acetic acid, mixing by inversion). Slides were prepared in a Thermotron (CDS-5 Cytogenetics Drying Chamber). Hybridization was carried out according to manufacturer's instructions with probes specific for human chromosomes 21 (LSI21, Abbott Molecular, Abbott Park, IL, USA), and 8 (ETO (8q21)/AML1(21q22), (Cytocell, Cambridge, UK). Nuclei were enumerated using a Zeiss Axioplan2 epifluorescence microscope and imaged by an Axiocam MRm camera (Carl Zeiss, Munich, Germany) using Isis software version 5.1.110 (Metasystems, Frankfurt, Germany).
With standard hybridization and washing stringencies, both probes hybridized only to human and not murine DNA.
Statistical analysis
Calculation of the LDA results was performed by the software L-Calc Version 1.1 (StemSoft Software, Vancouver, Canada). The proportion of engrafted human cells is presented as the mean ± s.d. The significance of the differences between groups was determined by using Student's t-test.
Results
DS-ML cells engraft, migrate, and self-renew in vivo
Acute ML is maintained by a transplantable fraction of cells capable of continued reproduction, limited differentiation, and migration. 17, 18 To test whether these functional attributes extend to DS-ML, we analyzed the phenotype and migration of DS-MLinitiating cells by transplantation into immunodeficient NOD/ SCID recipients. Four out of nine samples (Table 1 ) generated a human monomorphic cell population in recipient bone marrow (Figures 1a and b) . Engrafted human DS-ML cells showed an immunophenotype consistent with ML (Figure 1c) , the presence of human trisomy 21 (Figures 1e and f) , and the concordant clone-specific GATA1 mutations harbored by the primary human DS-ML sample (Table 1) . Two DS-ML samples displayed a non-megakaryocytic blast phenotype supporting the emerging concept of ML in DS as a non-lymphoid leukemia that is defined by GATA1 mutations, a young age of onset, 19 and a frequent but not exclusive association with a megakaryocytic lineage phenotype. 20, 21 Leukemic infiltration was observed at noninjected bone marrow sites, such as the left femur, tibiae, pelvis, and sternum, as well as spleen (Figures 1c and 2a ) and skeletal muscle (Supplementary Figure 1) . DS-ML cells engrafted secondary and tertiary recipients (Table 1 ; Supplementary  Figure 2 ) establishing that they possess self-renewal potential. DS-ML-initiating cells had a broad range of frequency (Table 1) and were not enriched in CD34-positive/CD38-negative cell fractions (data not shown). Taken together, the findings show a functional profile of DS-ML-initiating cells that closely resembles AML in the non-DS population.
TL cells do not expand, but are able to persist in vivo from some samples TL cells were detected in the recipients of 2 of 11 samples after intrafemoral injection (Table 1) . In contrast to DS-ML, detectable TL cells were confined to the injected bone marrow site (right femur) and found neither in non-injected bone marrow nor extramedullary sites. TL cells expressing human CD61, CD34, and harboring a GATA1 mutation concord with the primary sample. The size of the graft was variable ranging from 0.6 to 81.2% CD45 þ cells. As the engraftment potential of putative initiating cells is not known nor the cellular kinetics, we cannot be certain if a rare cell engrafted and the graft we identify 5-7 weeks after transplant represents significant proliferation (Supplementary Table 2 ). Alternately, the injected cells could simply survive in this site. However, most studies of other acute leukemias argue that long-term persistence of even a small graft is not the result of persistence of injected cells, which are typically lost very quickly, but because of active proliferation from an initiating cells. 13 Regardless, the overall level of engraftment was much lower in the injected femur of TL samples compared with DS-ML (14.4 ± 24.0% human CD45-positive cells in 11 recipients of two TL samples with detectable TL cells vs 61.50 ± 28.0% in 16 recipients engrafted with four samples of DS-ML cells; P ¼ 0.00012) (Figures 2a and b) . In one available sample, the frequency of cells capable of generating a detectable TL cell population at the injected bone marrow site (right femur) of primary recipients was 1/4.9 Â 10 6 ( Table 1) . In secondary transplant experiments, these TL cell populations generated detectable TL cells, again limited to the site of injection, in one of eight recipients (Supplementary Figure 2) . In contrast to DS-ML, TL cells in this experimental assay lacked the ability to proliferate, migrate, and self-renew, but were able to survive in the recipient bone marrow for an extended period of time.
Mechanisms of TL progression and resolution
We hypothesized that DS-ML is initiated at a high rate by a specific event, that is GATA1 mutations, but promoted through the cooperation with second events that are shared with non-DS ML. We found an activating mutations in codon 13 of N-RAS, which is mutated in approximately 35% of human acute ML cases, 22 also in one of the nine DS-ML samples, but none of the 11 samples of TL (Table 1; Supplementary Table 1) . No mutations of K-RAS, FLT3, and c-KIT were detected. Of note, the N-RAS-mutated DS-ML sample was in the subset of samples engrafting NOD/SCID recipients (Table 1) . Mutations promoting ML in the general population, therefore, also seem to be capable of promoting the progression from TL to DS-ML. Only an estimated 20% of TL cases go on to develop DS-ML 4 usually within 3 years of the detection of TL at birth. 2 In our assay, only a fraction of TL samples survived, but did not proliferate in the bone marrow of adult murine recipients. We hypothesized, therefore, that TL blasts are adapted to the hematopoietic environment of the fetal liver and fail to thrive in the endosteal niche of postnatal bone marrow hematopoiesis (reviewed in Wilson and Trumpp 23 ). Thus, impaired interaction with components of the niche would impose a limited period of survival in postnatal bone marrow on all TL cells except those that during this time acquire additional mutations, such as N-RAS, and are transformed into DS-ML-initiating cells. To test this idea, we found decreased expression in TL compared with DS-ML samples of the hyaluronic acid receptor CD44, which normal hematopoietic stem cells 24 and cells initiating non-DS acute ML 25 use to interact with the bone marrow environment (Figure 3; Supplementary Figure 3) . In contrast, the expression of the SDF-1 receptor CXCR4 (CD184), which together with its ligand is essential for myeloid blood cell formation in bone marrow but not the fetal liver, 26, 27 was not statistically different in TL and DS-ML. These data are in keeping with our hypothesis of differential ability to interact with the microenvironment between these two disease phases.
Discussion
In summary, our results accord well with the concept that TL and DS-ML are uniquely discernable and successive stages of transformation to ML. 3, 28 TL likely arises from fetal liver hematopoietic progenitor cells after the acquisition of GATA1 mutations in the context of cellular trisomy 21. This hypothesis is supported by the detection of GATA1 mutations in DS fetal liver cells, 29 expanded numbers of megakaryocyte-erythroid progenitor cells during DS fetal hematopoiesis, 30 and the increased proliferative capacity conferred to murine fetal liver GATA1 mutations of all engrafted samples were shown to be concordant with those present in the primary human cell samples. c Primary sample; codon 13 of N-RAS (NC_000001.10; nucleotide 115258813-5).
d Primary sample; deletion involving exon 2 and intron 1; nucleotide numbers refer to the genomic DNA sequence of human GATA1 (NW_927703). e Two recipients each were injected with a DS-ML bone marrow and a DS-ML peripheral blood sample, respectively. f Three recipients were engrafted by a DS-ML bone marrow sample, one recipient by a peripheral DS-ML blood sample. hematopoietic progenitors by the expression of a mutant GATA1 protein. 31 We observed that DS-ML-initiating cells possess a functional repertoire that is equivalent to AML of individuals without DS when assessed in vivo by the NOD/SCID transplant assay. In contrastFand in agreement with the postnatal phenotype of TL in human beingsFsome TL cells in this assay take up an existence of passive survival that provides latent targets for the eventual transformation to DS-ML during early infancy by second mutations, such as N-RAS. Leukemia-promoting second mutations are under intense investigation. 14, 32 Keeping the impact of host factors on the characterization of human leukemia-initiating cells in vivo in mind, 33, 34 we observed distinct TL and DS-ML phenotypes in NOD/SCID recipients, which not only reproduce these mechanistically relevant human disorders, but can now be used to test in vivo the functional relevance of putative second events.
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